Guidance Archives - Page 93 of 637

1 minute read

Westrock Coffee Says In Fiscal 2024 Co Expects Consolidated Adjusted EBITDA To Be Between $60M-$80M

February 15, 5:38 PM

2024 OutlookThe Company expects consolidated Adjusted EBITDA to be between $60 million and $80 million in fiscal 2024. The guidance range is necessarily broad to account for the range of results the Company may

WEST

3 minute read

Westrock Coffee Provides Business Announcements, Update On Preliminary FY23 Results, Initial 2024 Outlook; Sees FY23 Adjusted EBITDA To Fall Near The Low End Of Its Previously Disclosed Guidance Range Of $45M-$50M

By Benzinga Newsdesk

February 15, 5:38 PM

Announces Expansion of Capabilities at its New Extract and RTD Facility in Conway, Arkansas Announces Letter of Intent for Joint Venture with Select Milk Producers in New Extended Shelf Life and Aseptic, Multi-Serve

WEST

1 minute read

Cooper-Standard Holdings Sees FY24 Revenue $2.8B-$2.9B Vs $3B Est.

By Benzinga Newsdesk

February 15, 5:33 PM

OutlookIndustry projections for 2024 global light vehicle production anticipate volumes essentially in line with 2023 levels. The Company expects to continue leveraging enhanced commercial agreements and operating

CPS

3 minute read

T2 Biosystems Announces Preliminary Q4 Revenue Of $1.7M Vs $2.4M Est.; FY23 Revenue Of $7.2M Vs $7.9M Est.; FY24 Revenue Of $10M-$11M Vs $10.8M Est

By Benzinga Newsdesk

February 15, 5:24 PM

T2 Biosystems, Inc. (NASDAQ:TTOO) (the "Company"), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced preliminary unaudited financial and operational results

TTOO

1 minute read

Why Is Women Health-Focused Organon Stock Trading Higher On Thursday?

By Vandana Singh

February 15, 4:39 PM

Organon exceeds Q4 2023 revenue expectations, reaching $1.6 billion. Women's Health thrives with 7% revenue increase, driven by Follistim AQ's 63% growth. Biosimilar revenue surges by 49%.

OGN

3 minute read

Why Is Alnylam Pharmaceuticals Stock Trading Lower On Thursday?

By Vandana Singh

February 15, 4:29 PM

Alnylam Pharmaceuticals' updates on HELIOS-B Phase 3 study and FDA clearance for ALN-APP Phase 1 study. Fiscal year 2024 guidance of $1.4 billion–$1.5 billion in combined net product revenues.

ALNY

1 minute read

Why Is Zebra Technologies Stock Shooting Higher Thursday?

By Anusuya Lahiri

February 15, 2:37 PM

Zebra Technologies Corp reported Q4 FY23 net sales decline of 32.9%, beating expectations. Adjusted EPS also beat with stock price rising. Zebra expects net sales to decrease in Q1 but increase for FY24.

ZBRA

2 minute read

West Pharmaceutical’s 2024 Outlook Cautious, Analysts Remain Optimistic

By Vandana Singh

February 15, 2:17 PM

West Pharmaceutical Services reports Q4 2023 adjusted EPS at $1.83, surpassing consensus. Quarterly sales hit $732 million missing estimates. 2024 guidance hints at moderated organic growth, emphasizing inventory management strategies.

WST

1 minute read

Government Service Provider GEO Group Shares Are Higher Today: What’s Going On?

By Lekha Gupta

February 15, 2:13 PM

GEO Group reported Q4 FY23 revenue of $608.3M, beating consensus. Adjusted EBITDA fell to $129M while adjusted EPS of $0.29 surpassed consensus. Company reduced total net debt by $197M.

GEO